- $83.81bn
- $101.99bn
- £31.38bn
- 70
- 69
- 83
- 88
REG - GlaxoSmithKline PLC - ViiV positive ph3 data for long acting injectable
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Total Voting Rights
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - GSK response to SFO Statement
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding Replacement
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
Announcement